Skip to main content
    F

    Foghorn Therapeutics Inc (FHTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.89
    +0.04 (+2.16%)

    Market Cap: $109.86M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    40%(10/25)
    Avg Surprise
    -14.16%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.25
    Range$-0.41 - $-0.15
    7 analysts
    EPS Revisions
    1
    0
    7d
    4
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.24-4.8%
    60d ago$-0.24-4.8%
    30d ago$-0.23-9.3%
    7d ago$-0.23-9.3%
    Current$-0.25
    Revenue Consensus
    $7M
    Range$0 - $12M
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.13
    Range$-0.42 - $0.10
    8 analysts
    Revenue Consensus
    $6M
    Range$-3678760 - $21M
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.13---
    Sep 26EST
    		-$-0.25---
    Jun 26
    Reported Aug 6
    		$-0.10N/A+56.52%Beat+64.3%
    Mar 26
    Reported May 7
    		$-0.29$-0.31+6.45%Beat+3.3%
    Dec 25
    Reported Mar 11
    		$-0.37$-0.26-41.14%Miss-21.8%
    Sep 25
    Reported Nov 5
    		$-0.25$-0.31+19.35%Beat+19.4%
    Jun 25
    Reported Aug 5
    		$-0.28$-0.32+12.50%Beat+37.8%
    Mar 25
    Reported May 14
    		$-0.30$-0.29-3.45%Miss+49.2%
    Dec 24
    Reported Mar 6
    		$-0.30$-0.28-7.14%Miss+47.4%
    Sep 24
    Reported Nov 4
    		$-0.31$-0.43+27.91%Beat+8.8%
    Jun 24
    Reported Aug 8
    		$-0.45$-0.64+29.69%Beat+35.7%
    Mar 24
    Reported May 6
    		$-0.59$-0.59+0.00%Beat+19.2%
    Dec 23
    Reported Mar 7
    		$-0.57$-0.76+25.00%Beat+17.4%
    Sep 23
    Reported Nov 2
    		$-0.34$-0.65+47.69%Beat+45.2%
    Jun 23
    Reported Aug 4
    		$-0.70$-0.69-1.45%Miss-6.1%
    Mar 23
    Reported May 8
    		$-0.73$-0.72-1.39%Miss-12.3%
    Dec 22
    Reported Mar 9
    		$-0.69$-0.54-27.78%Miss+6.8%
    Sep 22
    Reported Nov 8
    		$-0.62$-0.50-24.00%Miss+12.7%
    Jun 22
    Reported Aug 9
    		$-0.66$-0.41-60.98%Miss-4.8%
    Mar 22
    Reported May 9
    		$-0.65$-0.47-38.30%Miss-4.8%
    Dec 21
    Reported Mar 10
    		$-0.74$-0.49-51.02%Miss+60.2%
    Sep 21
    Reported Nov 9
    		$-0.71$-0.59-20.34%Miss+77.2%
    Jun 21
    Reported Aug 10
    		$-0.63$-0.59-6.78%Miss+51.2%
    Mar 21
    Reported May 11
    		$-0.62$-0.55-12.73%Miss-
    Dec 20
    Reported Mar 18
    		$-1.86$-0.45-313.33%Miss-
    Sep 20
    Reported Oct 23
    		$-3.12$-2.69-15.99%Miss-
    Jun 20
    Reported Sep 2
    		$-1.29$-2.42+46.69%Beat-

    Key Metrics

    Valuation
    P/E Ratio-1.88EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-175.80%Operating Margin-54.80%
    ROE-470.40%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio3.36xQuick Ratio3.36x
    Trading Statistics
    Beta3.01Avg Volume1.32M
    52-Week High$7.6152-Week Low$1.79

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.96
    SMA 20$2.83
    SMA 50$4.59
    SMA 200$4.90
    EMA 10$2.16
    EMA 20$2.75
    EMA 50$3.82
    EMA 200$4.62

    MACD

    Line: -0.78Signal: -0.77Hist: -0.01

    ADX

    ADX: 58.3+DI: 7.6-DI: 42.3

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down60.0
    PSAR$1.99

    Bollinger Bands

    Upper Band$4.71
    Lower Band$0.96
    %B Position13235%(Upper)
    Band Width0.25

    RSI (14-Day)

    Oversold
    16.7

    Momentum Oscillators

    Stoch %K3.9
    Stoch %D4.7
    Williams %R-94.5
    ROC (10d)-35.3%
    Momentum-1.03
    CCI (20d)-74.1
    MFI (14d)11.1

    Volatility Measures

    ATR (14d)$0.28(15.0%)
    StdDev (20d)0.94
    Hist Vol130.0%(High)

    Volume Flow

    VWAP$1.87
    OBV-20.2M
    AD Line-1.8M
    CMF (20d)0.088

    Volume Metrics

    Avg Vol (20d)1.4M
    Vol Ratio0.2x(Low)
    VWMA (20d)$2.74

    Pivot Points

    R3$1.98
    R2$1.94
    R1$1.89
    Pivot Point$1.85
    S1$1.80
    S2$1.76
    S3$1.71

    Advanced Oscillators

    TSI-67.50
    Ultimate Osc46.6
    KST-568.84

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$16.07M$3.27M$9.25M$8.15M$7.56M$5.95M$2.86M$7.81M$6.89M$5.05M$5.77M$17.48M
    Cost of Revenue$0$0$802,000$0$0$0$761,000$0$0$0$852,000$0
    Gross Profit$16.07M$3.27M$9.25M$8.15M$7.56M$5.95M$2.86M$7.81M$6.89M$5.05M$5.77M$17.48M
    Operating Expenses$24.88M$24.84M$33.13M$26.65M$28.65M$28.86M$26.86M$31.66M$33.52M$33.24M$31.23M$34.56M
    R&D$18.52M$18.26M$22.05M$20.00M$21.79M$21.63M$20.51M$24.69M$23.80M$25.53M$24.20M$26.25M
    SG&A$6.35M$6.58M$6.80M$6.65M$6.86M$7.24M$6.35M$6.97M$7.33M$7.71M$7.02M$8.31M
    Operating Income$-8,805,000$-21,573,000$-23,878,000$-18,501,000$-21,097,000$-22,913,000$-24,005,000$-23,852,000$-26,632,000$-28,194,000$-25,458,000$-17,081,000
    Interest Income$1.61M$1.74M$1.71M$2.03M$2.31M$2.69M$3.10M$3.50M$2.87M$2.44M$2.66M$2.75M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-7,191,000$-19,875,000$-21,664,000$-15,849,000$-17,936,000$-18,834,000$-19,503,000$-19,122,000$-22,979,000$-25,016,000$-22,120,000$-13,607,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$1.99M$738,000
    Net Income$-7,191,000$-19,875,000$-21,664,000$-15,849,000$-17,936,000$-18,834,000$-19,503,000$-19,122,000$-22,979,000$-25,016,000$-24,106,000$-14,345,000
    EBITDA$-9,193,000$-21,767,000$-22,880,000$-17,385,000$-19,840,000$-21,517,000$-23,407,000$-23,669,000$-25,763,000$-27,174,000$-24,423,000$-16,151,000
    EBIT$-8,805,000$-21,617,000$-23,376,000$-17,881,000$-20,245,000$-21,526,000$-22,599,000$-22,617,000$-25,849,000$-27,455,000$-24,780,000$-16,360,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about FHTX

    News

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX

    Pomerantz LLP is investigating Foghorn Therapeutics Inc. (NASDAQ: FHTX) on behalf of investors following a significant stock price drop. The investigation follows Foghorn's announcement that it would not advance its...

    PR Newswire•10/15/26•Bearish

    Foghorn Therapeutics faces securities fraud pro...

    Foghorn Therapeutics is under investigation for securities fraud after discontinuing its FHD-909 and SMARCA2 degrader programs, ending a collaboration with Lilly...

    Pluang•10/13/26•Neutral

    Evercore ISI cuts Foghorn Therapeutics stock rating on trial failure By Investing.com

    Evercore ISI downgraded Foghorn Therapeutics (NASDAQ:FHTX) to In Line from Outperform and significantly cut its price target to $3.00 from $14.00 after the company discontinued its lead clinical program, FHD-909...

    Investing.com Canada•10/13/26•Bearish

    FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS Law

    Schall, Brown & Schwartz LLP (SBS) has launched an investigation into Foghorn Therapeutics Inc. (FHTX) for potential securities law violations. This follows a significant stock drop after Foghorn and Lilly decided not...

    Business Wire•10/11/26•Bearish

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX

    Pomerantz LLP is investigating potential securities fraud claims against Foghorn Therapeutics Inc. after the company announced it would not advance its FHD-909 program with Lilly and would also halt the Selective SMARCA2...

    PR Newswire•10/8/26•Bearish

    FHTX Valuation and Fair Value

    P/E
    -1.9x
    P/B
    -1.6x
    See GNG's fair value

    FHTX Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -54.8%
    Net margin
    -175.8%
    ROE
    -470.4%
    FCF margin
    -229.4%

    FHTX Competitors

    CompanyTicker
    Cellectis SACLLS
    Tonix Pharmaceuticals Holding CorpTNXP
    vTv Therapeutics IncVTVT
    LENZ Therapeutics IncLENZ
    NRX Pharmaceuticals IncNRXP
    enGene Holdings Inc. Common StockENGN
    TuHURA Biosciences IncHURA
    Stereotaxis IncSTXS

    Sector: Healthcare

    FHTX Analyst Ratings

    Consensus
    Buy
    Analysts
    10
    Strong Buy
    1
    Buy
    9
    Hold
    0
    Sell
    0
    Strong Sell
    0

    FHTX Bull Case vs Bear Case

    Bull case

    • FHTX grew quarterly revenue 112.7% year over year.
    • 100.0% of FHTX's analyst ratings are Buy or Strong Buy.

    Bear case

    • FHTX has a -175.8% net profit margin.

    FHTX Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    8.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.25
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    4 up, 1 down

    Frequently Asked Questions About FHTX

    Does FHTX pay dividends?

    Foghorn Therapeutics Inc (FHTX) does not currently pay a regular dividend.

    What is FHTX's market cap?

    Foghorn Therapeutics Inc (FHTX) has a market capitalization of $109.86M with a current stock price of $1.89.

    Related stocks

    Sector: Healthcare

    All stocks starting with F

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In